Drug Profile
Paroxetine - Novo Nordisk
Alternative Names: Aropax; BRL 29060; BRL 29060A; Deroxat; Divarius; FG 7051; Frosinor; Motivan; NNC 207051; Paxil; Paxil CR; Seroxat; SI 211103; TagonisLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer GlaxoSmithKline KK; GSK; Novo Nordisk; Scios; Vectura
- Class Antidepressants; Anxiolytics; Benzodioxoles; Fluorobenzenes; Irritable bowel syndrome therapies; Piperidines; Small molecules
- Mechanism of Action Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
- No development reported Anxiety disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in Mexico (PO, Tablet)
- 29 Sep 2023 GlaxoSmithKline plans a phase I trial for Anxiety disorders (In volunteers) in September 2023 (PO) (NCT06065735)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma